Anaphore raises $25M to accelerate Atrimers development

California, USA-based Anaphore has raised $25.0 million in series A financing led by 5AM Ventures, Versant Ventures and Apposite Capital.  The proceeds will be used to accelerate development of Atrimers - a new  class of protein therapeutics the company is developing to address  significant unmet medical needs in immune-mediated diseases and  oncology.

Atrimers are novel drug candidates engineered from a fully-human serum  protein that is naturally secreted as a trimeric structure. Anaphore's  proprietary protein engineering platform - TrimerX - provides multiple  approaches to generate Atrimers, therapeutics with biological,  manufacturing and commercial advantages over traditional drugs such as  antibodies, smaller protein scaffolds, and small molecules. Atrimers  and the TrimerX platform are protected by significant intellectual  property including over 13 patent families.